Physician profile
Jenna Jacobs
NPI 1215752597
$2,754.62
in general payments reported to CMS, 2019-2025
28 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.37 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Travel and Lodging: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.74 |
| Travel and Lodging | $452.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $481.71 | 2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $445.46 | 2025 | Austedo Xr |
| Abbvie INC. | $374.42 | 2025 | |
| Sk Life Science, INC. | $339.00 | 2025 | Xcopri |
| Livanova USA, INC. | $141.94 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $137.33 | 2025 | |
| Amneal Pharmaceuticals LLC | $98.06 | 2024-2025 | Crexont |
| Axsome Therapeutics, INC. | $78.41 | 2025 | Symbravo, Sunosi |
| Lundbeck LLC | $77.54 | 2025 | Vyepti |
| Ucb, INC. | $50.54 | 2025 | Nayzilam |
| Catalyst Pharmaceuticals, INC. | $49.39 | 2025 | |
| Springworks Therapeutics, INC. | $47.34 | 2025 | Gomekli |
| Averitas Pharma INC. | $45.23 | 2025 | Qutenza |
| Merz Pharmaceuticals, LLC | $38.52 | 2025 | Xeomin, Inbrija |
| Pfizer INC. | $37.63 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $35.94 | 2025 | Daybue |
| Jazz Pharmaceuticals INC. | $32.57 | 2025 | |
| Intrabio INC | $31.55 | 2025 | Aqneursa |
| Astrazeneca Pharmaceuticals LP | $25.36 | 2025 | Wainua |
| Biomarin Pharmaceutical INC. | $24.57 | 2025 | Brineura |
| Harmony Biosciences LLC | $23.07 | 2025 | |
| Genzyme Corporation | $21.87 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.73 | 2025 | |
| Tanabe Pharma America, INC. | $21.58 | 2025 | Radicava |
| Amgen INC. | $20.75 | 2025 | Uplizna |
| Lilly USA, LLC | $20.51 | 2025 | Kisunla |
| Otter Pharmaceuticals, LLC | $17.36 | 2025 | Sympazan |
| Kedrion Biopharma, INC. | $15.24 | 2025 | Albuked, Gammaked, Rhogam Ultra-Filtered Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.